StockNews.com Begins Coverage on Aeterna Zentaris (NASDAQ:AEZS)

Analysts at StockNews.com assumed coverage on shares of Aeterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) in a report released on Thursday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Aeterna Zentaris Stock Performance

Shares of AEZS opened at $8.52 on Thursday. The company has a market capitalization of $10.31 million, a P/E ratio of -0.57 and a beta of 1.60. The business’s 50-day moving average is $8.14 and its two-hundred day moving average is $7.71. Aeterna Zentaris has a fifty-two week low of $5.44 and a fifty-two week high of $12.80.

Aeterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) last announced its quarterly earnings results on Wednesday, March 27th. The biopharmaceutical company reported ($4.64) earnings per share for the quarter, missing the consensus estimate of ($3.88) by ($0.76). Aeterna Zentaris had a negative net margin of 760.32% and a negative return on equity of 73.62%. The company had revenue of $0.12 million for the quarter.

Aeterna Zentaris Company Profile

Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications; and AEZS-150, a delayed clearance parathyroid hormonefusion polypeptide that is in preclinical trail for the treatment of hypoparathyroidism in adults.